Evidence map›Paper›PMID 34849546›Full record

Trial reportThe American journal of clinical nutrition2022

Clinical and biomarker modifiers of vitamin D treatment response: the Multi-Ethnic Study of Atherosclerosis.

Simon Hsu, David K Prince, Kayleen Williams, Norrina B Allen, Gregory L Burke, Andrew N Hoofnagle, Xiaohui Li, Kiang J Liu, Robyn L McClelland, Erin D Michos and 9 more

Registry-linked trialOpen access · greenAbstract readRandomized Controlled Trial
PubMed Full text at PMC Publisher
In one paragraph

Trial report in The American journal of clinical nutrition, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT02925195 (Multi Ethnic Study of Atherosclerosis Individualized Response to Vitamin D Treatment Study), which is not on this map. Cited by 5 papers.

0numbers the graph read from it
0cells of the map it votes in
5citing papers in PubMed
1.2field-weighted citation impact, top 21% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

NCT02925195 nacompletednot on this map

Multi Ethnic Study of Atherosclerosis Individualized Response to Vitamin D Treatment Study

TypeinterventionalSponsorUniversity of WashingtonRan2017 to 2022Enrolled666ConditionsCharacteristics That Modify the Response to Cholecalciferol TreatmentArmsVitamin D3, Placebo
3 · Its place in the literature

Who cites it

5 citing papers in PubMed, 10 citations in OpenAlex.

  1. Trial
  2. Article
  3. Article
  4. Article
  5. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

19 authors at 9 institutions in 1 country.

Simon HsuDivision of Nephrology and Kidney Research Institute, Department of Medicine, University of Washington, Seattle, WA, USA.ORCID 0000-0003-3780-294X
David K PrinceDivision of Nephrology and Kidney Research Institute, Department of Medicine, University of Washington, Seattle, WA, USA.
Kayleen WilliamsDepartment of Biostatistics, University of Washington, Seattle, WA, USA.
Norrina B AllenDepartment of Internal Medicine, Northwestern University, Chicago, IL, USA.
Gregory L BurkeDivision of Public Health Sciences Wake Forest School of Medicine, Winston-Salem, NC, USA.
Andrew N HoofnagleDepartment of Laboratory Medicine, University of Washington, Seattle, WA, USA.
Xiaohui LiThe Institute for Translational Genomics and Population Sciences, Department of Pediatrics, The Lundquist Institute for Biomedical Innovation at Harbor-UCLA Medical Center, Torrance, CA, USA.
Kiang J LiuDepartment of Preventive Medicine, Northwestern University, Chicago, IL, USA.
Robyn L McClellandDepartment of Biostatistics, University of Washington, Seattle, WA, USA.
Erin D MichosDivision of Cardiology, Department of Medicine, Johns Hopkins University, Baltimore, MD, USA.
Bruce M PsatyCardiovascular Health Research Unit, Departments of Medicine, Epidemiology, and Health Services, University of Washington, Seattle, WA, USA.
Steven J SheaDepartment of Medicine, Columbia University College of Physicians and Surgeons, New York, NY, USA.
Kenneth M RiceDepartment of Biostatistics, University of Washington, Seattle, WA, USA.
Jerome I RotterThe Institute for Translational Genomics and Population Sciences, Department of Pediatrics, The Lundquist Institute for Biomedical Innovation at Harbor-UCLA Medical Center, Torrance, CA, USA.
David SiscovickNew York Academy of Medicine, New York, NY, USA.
Russell P TracyDepartment of Biochemistry, University of Vermont, Burlington, VT, USA.
Karol E WatsonDepartment of Medicine, David Geffen School of Medicine at UCLA, Los Angeles, CA, USA.
Bryan R KestenbaumDivision of Nephrology and Kidney Research Institute, Department of Medicine, University of Washington, Seattle, WA, USA.
Ian H de BoerDivision of Nephrology and Kidney Research Institute, Department of Medicine, University of Washington, Seattle, WA, USA.
University of Washington · USNorthwestern University · USUCLA Medical Center · USColumbia University · USJohns Hopkins University · USNew York Academy of Medicine · USUniversity of California, Los Angeles · USUniversity of Vermont · USWake Forest University · US

Funding

UCLA Clinical and Translational Science InstituteUL1TR001881 · UNIVERSITY OF CALIFORNIA LOS ANGELES · 2025 to 2025
$9.9M
PILOT STUDY--CLINICAL NUTRITION RESEARCHP30DK035816 · UNIVERSITY OF WASHINGTON · 1986 to 2025
$7.0M
Pilot & Feasibility ProgramP30DK063491 · UNIVERSITY OF CALIFORNIA, SAN DIEGO · 2003 to 2025
$5.4M
NCATS NIH HHS UL1 TR001881NCRR NIH HHS UL1 RR033176NHLBI NIH HHS R01 HL096875NIDDK NIH HHS F32 DK128986NIDDK NIH HHS P30 DK035816NIDDK NIH HHS P30 DK063491
6 · The paper itself

Abstract

backgroundDifferent 25-hydroxyvitamin D [25(OH)D] thresholds for treatment with vitamin D supplementation have been suggested and are derived almost exclusively from observational studies. Whether other characteristics, including race/ethnicity, BMI, and estimated glomerular filtration rate (eGFR), should also influence the threshold for treatment is unknown.

objectivesThe aim was to identify clinical and biomarker characteristics that modify the response to vitamin D supplementation.

methodsA total of 666 older adults in the Multi-Ethnic Study of Atherosclerosis (MESA) were randomly assigned to 16 wk of oral vitamin D3 (2000 IU/d; n = 499) or placebo (n = 167). Primary outcomes were changes in serum parathyroid hormone (PTH) and 1,25-dihydroxyvitamin D [1,25(OH)2D] concentrations from baseline to 16 wk.

resultsAmong 666 participants randomly assigned (mean age: 72 y; 53% female; 66% racial/ethnic minority), 611 (92%) completed the study. The mean (SD) change in PTH was -3 (16) pg/mL with vitamin D3 compared with 2 (18) pg/mL with placebo (estimated mean difference: -5; 95% CI: -8, -2 pg/mL). Within the vitamin D3 group, lower baseline 25-hydroxyvitamin D [25(OH)D] was associated with a larger decline in PTH in a nonlinear fashion. With baseline 25(OH)D ≥30 ng/mL as the reference, 25(OH)D <20 ng/mL was associated with a larger decline in PTH with vitamin D3 supplementation (-10; 95% CI: -15, -6 pg/mL), whereas 25(OH)D of 20-30 ng/mL was not (-2; 95% CI: -6, 1 pg/mL). A segmented threshold model identified a baseline 25(OH)D concentration of 21 (95% CI: 13, 31) ng/mL as an inflection point for difference in change in PTH. Race/ethnicity, BMI, and eGFR did not modify vitamin D treatment response. There was no significant change in 1,25(OH)2D in either treatment group.

conclusionsOf characteristics most commonly associated with vitamin D metabolism, only baseline 25(OH)D <20 ng/mL modified the PTH response to vitamin D supplementation, providing support from a clinical trial to use this threshold to define insufficiency. This trial was registered at clinicaltrials.gov as NCT02925195.

Indexed as

AtherosclerosisVitamin D DeficiencyAgedBiomarkersCalcifediolCholecalciferolDietary SupplementsEthnicityFemaleHumansMaleMinority GroupsParathyroid HormoneVitamin DVitaminsBiomarkersCalcifediolCholecalciferolParathyroid HormoneVitamin DVitaminscholecalciferolHbA1c harmonization programrandomized clinical trialstandardizationvitamin Dvitamin D deficiencyvitamin D insufficiencyvitamin D standardization program

Identifiers

PMID34849546
PMCPMC8895207
OpenAlexW3214796502

What Socratic holds

Textmetadata
Read underepoch 390

Registered trials

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.